Replies to post #92513 on Avid Bioservices Inc (CDMO)

[cjgaddy]

Bob, for 1st-Line NSCLC, also recall FTM’s Tables for P+C/Alone prev. Trials in Front-Line NSCLC…
• The mean MOS is 9.8 mos. for the 12 trials (range 8.1 – 13.0)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76905176


= = = = = = = = = = = = = =
Look at the MOS reported for the P+C/Alone arm in this Avastin trial:
(P+C = Paclitaxel + Carboplatin)
AVASTIN E4599/n=434 Ph.III Trial in Front-Line NSCLC:
• P+C/alone = 10.3 mos.
• Avastin+PC=12.3 mos.
From: http://www.nejm.org/doi/pdf/10.1056/NEJMoa061884

[Robert C Jonson]

CJ, that looks convincing, so it looks very much like the 1st line control arm MOS should have been reached by now. Hope you hear something from IR.

THanks!

Bob